\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationOnline
ProgrammesWe have been informed that the 2nd EDF Online matchmaking event has now opened for registrations.
The event will take place virtually on December 10th, 2024, from 1:00PM to 6:00PM CET, and will be introduced by a best practices webinar session in the morning, from 11:00AM to 12:00PM CET.
Registrations are now open for participants to fill in their profiles. After having registered, you will be able to access to wide catalogue of potential partners and to send/receive meetings requests to be attended on that day.
The link to register and participate is the following: https://server.matchmaking-studio.com/en/EuropeanDefenceFundMatchmakingDayDec2024/.
This matchmaking event enables EDF potential applicants to reach out to partners and to prepare the next EDF calls deadline of 2025. This is also a chance to ask your questions to the Belgian NFP-team regarding several aspects such as the scope of your project, funding rates, eligibility of partners, costs, etc.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Climate, Energy, Mobility Agro-Food, Environment Missions
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
